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Abstract
Background: Current evidence indicates that
probiotic supplementation significantly reduces all-
cause mortality and definite necrotising enterocolitis
without significant adverse effects in preterm
neonates. As the debate about the pros and cons of
routine probiotic supplementation continues, many
institutions are satisfied with the current evidence and
wish to use probiotics routinely. Because of the lack
of detail on many practical aspects of probiotic
supplementation, clinician-friendly guidelines are
urgently needed to optimise use of probiotics in
preterm neonates.
Aim: To develop evidence-based guidelines for
probiotic supplementation in preterm neonates.
Methods: To develop core guidelines on use of
probiotics, including strain selection, dose and
duration of supplementation, we primarily used the
data from our recent updated systematic review of
randomised controlled trials. For equally important
issues including strain identification, monitoring for
adverse effects, product format, storage and transport,
and regulatory hurdles, a comprehensive literature
search, covering the period 1966-2010 without
restriction on the study design, was conducted, using
the databases PubMed and EMBASE, and the
proceedings of scientific conferences; these data were
used in our updated systematic review.
Results: In this review, we present guidelines,
including level of evidence, for the practical aspects
(for example, strain selection, dose, duration, clinical
and laboratory surveillance) of probiotic
supplementation, and for dealing with non-clinical
but important issues (for example, regulatory
requirements, product format). Evidence was
inadequate in some areas, and these should be a
target for further research.
Conclusion: We hope that these evidence-based
guidelines will help to optimise the use of probiotics
in preterm neonates. Continued research is essential
to provide answers to the current gaps in knowledge
about probiotics.
Background
Despite the advances in neonatal intensive care over
past 20 years [1], the incidence of necrotising enterocoli-
tis (NEC) in preterm neonates has not changed signifi-
cantly. The mortality (approximately 20 to 25%) and
morbidity related to definite (greater than stage II) NEC,
including prolonged hospitalisation [2], survival with
short-bowel syndrome [3,4] and long-term neurodeve-
lopmental impairment (NDI) continues to be high, espe-
cially in preterm or extremely low birth weight (ELBW)
(birth weight < 1000 g, gestation < 28 weeks) neonates
needing surgery for this illness [5]. Mortality reaches
nearly 100% in children with extensive and full-thickness
necrosis of the gut [6,7].
Antenatal use of glucocorticoids, with postnatally, pre-
ferential feeding with fresh human milk, aggressive pre-
vention and treatment of sepsis, and a cautious uniform
approach to enteral feeds are the strategies available to
prevent NEC [8]. Previous systematic reviews of rando-
mised controlled trials (RCTs) showed that probiotic
supplementation significantly reduces the risk of definite
NEC, all-cause mortality and the time to reach full ent-
eral feeds (~120 to 150 ml/kg/day of milk) in preterm
neonates [9-11]. Based on these results, reports have
indicated that routine probiotic supplementation is justi-
fied, except for ELBW neonates, given the lack of speci-
fic data on this high-risk cohort [12,13]. Our most
recent updated systematic review and meta-analysis con-
firmed previous results, while improving their precision
and reducing the likelihood of these being due to
chance alone (Table 1) [14]. Moreover, trial sequential
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evidence of at least 30% reduction in the incidence of
N E C .T h e s ec o n c l u s i v er e s u l ts, along with those from
observational studies on routine use of probiotics, their
use in ELBW neonates [15,16], and their safety and pos-
sible benefits in terms of long-term NDI, justify a
change in practice if safe and suitable probiotic products
a r ea v a i l a b l e[ 1 7 ] .S o m eh a v es u p p o r t e do u rv i e w s[ 1 8 ] ,
b u to t h e r sc i t ed i f f i c u l t i e ss u c ha sp r o b l e m si np o o l i n g
data in the presence of clinical heterogeneity, reproduci-
bility of the results in different studies, role of breast
milk, pitfalls of TSA, lack of availability of safe and
effective products, development of antibiotic resistance,
cross-contamination and long-term adverse effects (AEs)
as reasons for opposing routine use of probiotics in pre-
term neonates [19-23]. We have previously addressed
these concerns [24], and pointed out that probiotic
research has completed a full circle, from basic science
[25] and cohort studies [26], to conclusive meta-analysis
[14], routine use [15], and long-term follow up [16,17].
Many level III neonatal units in Japan, Italy, Finland and
Columbia have been using probiotics routinely for over
a decade, and have not reported any significant AEs
[15,27,28]. Based on the quality and totality of the evi-
dence in the context of the related health burden and
the lack of equally effective therapies, we believe that
probiotics should be offered routinely to preterm neo-
nates. Additionally, from the perspective of a preterm
neonate or their family, there would need to be a good
reason to ignore the evidence base for using probiotics
to prevent NEC. Offering probiotics routinely, but still
within a framework of research other than placebo-con-
trolled trials, is the way forward to deal with the as yet
unanswered questions [14,24]. As the debate about the
pros and cons of routine probiotic supplementation con-
tinues, many institutions are satisfied with the current
evidence and wish to use probiotics routinely. Because
of the lack of detail on many practical aspects of probio-
tic supplementation, clinician-friendly guidelines are
urgently needed to optimise use of probiotics in preterm
neonates.
Because of the vast scope of the field, we aimed to
conduct a comprehensive rather than a conventional
systematic review in order to develop evidence-based
guidelines for using probiotics in preterm neonates, and
we indicate areas for further exploration of this new
frontier.
Methods
To develop the core guidelines for strain selection, age
at start, dose and duration of the supplementation, we
primarily used the data from RCTs of probiotics in pre-
term neonates from our recent updated systematic
review [14].
For equally important issues such as strain identifica-
tion, AEs, product format, storage and transport, regula-
tory issues, ethics and parent information, the relevant
literature was searched in PubMed (1966 to October
2010) and EMBASE for the period 1980 to October
2010, and we also used the search engine Google.
PubMed was searched using the following terms: “Pro-
biotics"[MeSH] AND “Culture Techniques"[MeSH];
“Probiotics"[MeSH] AND “Classification"[MeSH]; “Pro-
biotics"[MeSH] AND “Bacterial Translocation"[MeSH];
“Probiotics"[MeSH] AND “Sepsis"[MeSH]; “Probiotics"[-
MeSH] AND “Informed Consent"[MeSH]; “Probiotics"[-
MeSH] AND “Legislation, Drug"[MeSH];
“Probiotics"[MeSH] AND ("Ethics"[MeSH] OR “Ethics
Committees"[MeSH] OR “Ethics Committees, Clinical"[-
MeSH] OR “Codes of Ethics"[MeSH] OR “Ethics Com-
mittees, Research"[MeSH] OR “Ethics, Clinical"[MeSH]
OR “Ethics, Professional"[MeSH] OR “Ethics, Medical"[-
MeSH] OR “Bioethics"[MeSH]); “Probiotics"[MeSH]
AND Refrigeration"[MeSH] “Probiotics"[MeSH] AND
“Quality Control"[MeSH]; “Probiotics"[MeSH] AND
“Quality Assurance, Health Care"[MeSH].
EMBASE was searched using the following terms: pro-
biotic.mp. or probiotic agent AND microbiological
examination/or culture medium/or methodology/or cul-
ture methods.mp. or culture technique/or bacterium
culture/; probiotic.mp. or probiotic agent AND antibio-
tic susceptibility.mp. or antibiotic sensitivity; probiotic.
mp. or probiotic agent AND Sepsis; probiotic.mp. or
probiotic agent AND bacterial translocation; probiotic.
mp. or probiotic agent AND legislation.mp. or licence/
or law/; probiotic.mp. or probiotic agent AND informed
consent; probiotics.mp. or probiotic agent AND tem-
perature/or drug storage/or drug packaging/or cold
chain.mp. or drug stability/or freezing/; probiotic.mp. or
probiotic agent quality assurance.mp. or quality control/.
The search covered studies in the neonatal, paediatric
and adult populations, and also in animal studies and in
vitro studies. Cross-references from the relevant studies
were also searched. Specific references that were used to
develop the guidelines are quoted in the main manu-
script of the review. All other essential or related refer-
ences are included in the appendices (see Additional file
Table 1 Updated systematic review results (Pediatrics
2010)
Outcome RR
a(95% CI) P value NNT
b (95% CI
c )
NEC 0.35 (0.23 to 0.55) 0.00001 25 (17 to 34)
Mortality 0.42 (0.29 to 0.62) 0.00001 20 (14 to 34)
Sepsis 0.98 (0.81 to 1.18) 0.80 N/A
d
aRelative risk.
bConfidence interval.
cNumbers needed to treat.
dNot available.
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the PubMed and EMBASE search strategies.
An attempt to search Google search engine using the
aforementioned terms was abandoned, as it resulted in
hits ranging from 838 to 1,690,000. PRISMA guidelines
for reporting the systematic review were followed where
applicable [29].
When establishing guidelines, it is preferable to grade
the level of evidence (LOE) depending on the type and
the quality of study. However, we found that there are
no validated and universally accepted methods for asses-
sing the quality of studies) especially for studies other
than RCTs), or for grading the LOE [30-37]. Our core
guidelines are based on the systematic review of RCTs
of probiotic supplementation in preterm very low birth
weight (VLBW) neonates. The quality of these trials was
assessed by the method recommended by the Cochrane
Neonatal Review Group and by Jadad scores, which are
commonly used but have not been validated [38,39].
The development and reporting of crucial aspects of
probiotics (for example, selection, manufacturing, trans-
port, storage, quality control (QC), and regulation) has
not necessarily followed the model of evidence-based
medicine, making it difficult to apply the principles of
LOE to every aspect of this intervention. It is also diffi-
cult to apply the conventional concept of study design
and LOE for bench research to practical issues such as
stability and taxonomy confirmation. We therefore
adopted a simple method of grading the LOE, based on
a pyramid of evidence hierarchy, with systematic reviews
of RCTs being at the top (best evidence) and a case ser-
ies being the bottom [33] (Figure 1). We believe that
this simple system for grading the LOE along with the
judgement of the readers will be adequate to permit
appropriate interpretation of the various aspects of the
guidelines.
Results
Selection of strains
Bifidobacteria and lactobacilli are the species of choice
in probiotics, given the evolution of the gut flora in
preterm neonates [40-42]. However, lactobacilli are a
minor component of the intestinal microbiota. In terms
of the rationale for species and strain selection, it is
important to note that there are many different mechan-
isms producing the benefits of probiotics and there are
also strain-specific effects. Bifidobacteria are the domi-
nant strains in infancy, and the combination of lactoba-
cilli and bifidobacteria is known to promote the growth
of indigenous lactic-acid bacteria (bifidogenic effect) by
formation of short-chain fatty acids as a product of the
fermentation process [41,43,44].
Strains isolated from humans are preferable because of
their natural occurrence, long-term record of safety in
infants, and adaptability to both mucosal and dairy eco-
systems [45,46]. Researchers have generally selected
strains belonging to bacterial species naturally present in
the intestinal flora of the species to be targeted (in this
case, humans), under the assumption that these bacteria
have a better chance of out-competing resident bacteria
and of establishing themselves at a numerically signifi-
cant level in their new host [45]. However, because
humans have shared such strains with other mammals
for millions of years, other researchers believe that their
origin is difficult to trace as they are present everywhere:
in human beings, animals, soil, food and water. Thus,
bovine strains may also be used if they have a good
record of safety and efficacy. It is the specificity of the
action rather than the source of the microorganism that
is important. The clinical significance of the origin of
strains may be evaluated in future trials [45,47-51]. The
probiotic strains that have been used in various RCTs in
preterm neonates are summarised in Table 2[52-62].
It is important to note that the probiotic effects are
strain-specific, and cannot be extrapolated to other
strains. The variability of the strains and protocols in
the trials included in our meta-analysis indicates that
the concept of strain-specific effects of probiotics may
not be relevant to prevention of NEC by probiotics.
Because of the various complex pathways involved in
the pathogenesis of NEC, different strains may benefit
by different pathways [63]. The benefits of different
Figure 1 Designations of levels of evidence. Figure from Merlin et al. BMC Medical Research Methodology 2009: 34, doi:10.1186/1471-2288-9-34.
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many probiotic effects are strain-specific, others may be
similar for very different probiotic organisms [64]. The
variation in the immunomodulatory effects between spe-
cies is generally larger than that between the strains of
the same species [65]. The rates of gut colonisation by a
probiotic strain also differ according to the age of the
host [52,66,67].
Evidence indicates that the functionality of a multi-
strain or multispecies probiotic could be more effec-
tive and more consistent than that of a monostrain
probiotic [46,68,69]. Researchers have also investigated
the adequacy of combinations of strains [70]. Coloni-
sation of an ecosystem providing a niche for more
than 400 species in combination with individually
determined host factors is anticipated to be more suc-
cessful with multistrain rather than monostrain pro-
biotic preparations [46,50,71,72]. The results of one
review indicated that multistrain probiotics showed
greater efficacy than single strains, including single
strains that were components of the mixtures them-
selves. It was unclear whether this was due to syner-
gistic interactions between strains or to the higher
probiotic dose used in some studies [73]. Based on the
complexity of normal gut flora and of NEC pathogen-
esis, and the multiple beneficial mechanisms of pro-
biotic strains, multistrain probiotics may be more
effective than single-strain probiotics [63,74].
However, the report of a consensus meeting of experts
states that a combination of probiotic strains in a pro-
duct does not necessarily add to the benefits of each
strain [75]. A high number of different strains is not,
in itself, indicative of greater efficacy than a lower
number of strains [75]. Clinical trials are needed to
address the benefits of single-versus multistrain pro-
biotic products in preterm neonates.
Our systematic review of RCTs indicates that the trials
reporting a significant decline in NEC used multistrain
products [55,56,60], whereas those reporting a lesser
decline used a single organism, such as Lactobacillus
rhamnosus GG [52-54]. Failure of Lactobacillus GG to
prevent NEC in the RCT reported by Dani et al.a n di n
the report of 12 years’ experience by Luoto et al.s u g -
gests that it may be prudent to avoid the use of this sin-
gle strain alone, pending further evidence [27,28,53].
The potential of Bifidobacterium animalis (subspecies
lactis) also needs to be explored [58,59,76].
U s i n gm o r et h a nt w oo rt h r e es t r a i n s( e a c hw i t ha n
optimal mass) may result in higher risk of translocation
because of the substantial increase in the total dose,
especially in ELBW neonates; however, without an opti-
mal mass of each component, a combination may not
be effective in assuring survival and colonisation by each
strain of the supplement. It is better to avoid untested
combinations, because strain combinations can be
antagonistic, compatible or synergistic [77].
Table 2 Probiotic protocols from trials included in the updated meta-analysis
Study Probiotic agent/s Dose and duration
Kitajima
1997 [52]
Bifidobacterium breve 0.5 × 10
9 cfu
a once daily from first feed for 28 days.
Dani 2002
[53]
Lactobacillus rhamnosus GG 6 × 10
9 cfu once daily from first feed until discharge
Costalos
2003 [54]
Saccharomyces boulardii 10
9/kg twice daily from first feed for 30 days
Bin Nun
2005 [55]
Bifidobacterium infantis, Streptococcus
thermophilus, Bifidobacterium bifidus
0.35 × 10
9 cfu B. infantis, 0.35 × 10
9 cfu S. thermophilus and 0.35 × 10
9 cfu B. bifidus
once daily from first feed to 36 weeks corrected age
Lin 2005
[56]
Lactobacillus acidophilus, B. infantis 1004356 L. acidophilus and 1015697 B. infantis organisms twice daily from day 7 until
discharge
Manzoni
2006 [57]
Lactobacillus casei 6×1 0
9 cfu once daily from 3 days to 6 weeks of age, or discharge from NICU
b
Mohan
2006 [28]
Bifidobacterium lactis 1.6 × 10
9 cfu once daily from day 1 to day 3; 4.8 × 10
9 cfu once daily from day 4 to
day 21
Stratiki
2007 [59]
B. lactis Preterm formula: 1 × 10
7 cfu/g started within 48 hours to 30 days
Lin 2008
[60]
B. bifidus, L. acidophilus 2×1 0
9 cfu daily for 6 weeks
Samanta
2009[61]
B. bifidus, B. lactis, B. infantis, L.s acidophilus 2.5 × 10
9 cfu daily until discharge
Rouge
2009 [62]
Bifidobacterium longum, Lactobacillus GG 1 × 10
8 cfu daily until discharge
aColony-forming units.
bNeonatal intensive-care unit.
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have previously been shown to be effective in RCTs,
provided the evidence indicates that there has been no
change or compromise in the manufacturing technique
[55,56].
Dose
An optimal mass or dose is essential for any probiotic
strain to survive and colonise the gut. The concept of
viability refers to the ability of the probiotic strain to
survive and proliferate in ‘adequate’ numbers to benefit
the host. It is hence expected that there will be an opti-
mal dose below which benefits may not occur, as survi-
val and proliferation to adequate numbers, after
overcoming the barriers such as gastric acid, bile and
competing flora, is not ensured [78,79]. Evidence indi-
cates that to be functional, probiotics have to be viable
and in sufficient dosage levels, typically 10
6 to 10
7 col-
ony-forming units (cfu)/g of product [46,80,81].
Conventional dose-response studies could be con-
ducted in preterm neonates; however the selected doses
will be arbitrary, and only guessed from what is known
about the gut ecosystem in preterm neonates. There is
no data on the toxic or lethal dose of probiotics for pre-
term neonates, and extrapolating from studies in other
populations and animal experiments is likely to be
incorrect [82]. An expert consensus report stated that ‘...
there is no standardised number of probiotic bacteria
that would ensure an effect [75]. The effective quantity,
for a given effect and a given strain, is the quantity
which has demonstrated an effect in the relevant human
intervention trial’. In addition, live probiotics have the
potential to replicate in the gut and lead to bacteremia.
Judicious consideration is hence important in applying
the principle of dose-response studies to this high-risk
population with associated poor nutrition, impaired
immune status and frequent exposure to infectious
agents [83]. Conducting crossover and forced-titration
(stepwise dose-escalation) dose-response studies will
also be difficult, as the incidence of NEC is known to
fluctuate over time. As for parallel design, the definition
of a target dose is subjective.
Based on the median dose used in the RCTs in pre-
term neonates (Table 2), we suggest that a daily dose of
3×1 0
9 cfu/day may be appropriate for neonates of less
than 32 weeks gestation. Currently, there are no data
available regarding a dose beyond which the risk of pro-
biotic complications will be high in ELBW neonates.
Until such data are available, we suggest that the start-
ing dose should be 1.5 × 10
9 cfu/day for ELBW neo-
nates until they reach enteral feeds of 50 to 60 ml/kg/
day. Halving the volume of the probiotic supplement
should also benefit these neonates because they are
often intolerant to large enteral volumes [84]. The
reduced dose is still expected to be beneficial, based on
the lower clinically effective doses used in the trials in
our updated meta-analysis [55].
Investigators of one recent trial suggested that the
daily probiotic dose in malnourished children should
preferably be given as a single rather than divided dose,
in view of the rapid decline of the strain mass in vivo
[85]. The osmotic load, pH and volume of a single dose
are crucial in ELBW neonates because of their inability
to tolerate even very small volumes of milk feeds in the
early days of life [86]. The nature of diluent (dextrose,
sterile water, saline, milk) and volume after dilution are
also important practical issues. The currently recom-
mended range of osmolarity of neonatal milk formulae
is 246 to 320 mOsm/kg [87]. The osmotic load of drugs
and milk additives is a concern in high-risk neonates
because of the risk of NEC [88-90]. Adequate dilution is
thus necessary to avoid undue hyperosmolarity.
When to start?
Because of the importance of early establishment of com-
mensal flora in preterm neonates [40,41,91], the probiotic
supplementation should be started as early as possible
before pathogens colonise or antibiotics destroy the pre-
vailing commensals. The earliest reported age at start of
supplementation was 4 hours of life, in the study by Satoh
et al. [15]. Otherwise most of the investigators assessed (7/
11) started the supplementation when the neonates were
ready for enteral feeds (Table 2). Clinical stability (for
example, no sepsis, patent ductus arteriosus, inotropes or
ileus) is desirable to ensuret h a tt h eg u tf u n c t i o nh a s
recovered after the initial illness, with minimal risk of
intolerance or translocation. The optimal protocol for pro-
biotic administration in ELBW neonates with intrauterine
growth restriction needs to be confirmed [92].
When to stop?
It is well known from animal and human (both adults and
children) studies that shedding of probiotic organisms in
the stool commonly stops about 2 to 3 weeks after the
probiotic supplement is stopped [48,69,78,93]. Hence con-
tinued administration is necessary to promote sustained
colonisation in preterm neonates until evidence is avail-
able for this high-risk population. Based on the published
trials (Table 2) and the inverse relation of gestational age
with NEC and all-cause mortality, it seems appropriate
that supplementation could be stopped after reaching the
corrected gestational age of 36 to 37 weeks, when the risk
of these adverse outcomes is minimal.
Supplementation in the presence of potentially
compromised gut integrity
The risk of probiotic translocation and sepsis is higher
in critically ill and/or extremely preterm neonates with
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be higher in the presence of high doses of a single
strain. The current evidence is inadequate to make clear
recommendations in this area [14]. Investigators
reported increased mortality in recipients of probiotic
(compared with placebo) in an RCT involving adults
with acute pancreatitis [99]. These findings may relate
to non-occlusive mesenteric ischemia in critical illness,
which is exacerbated by the added bacterial load itself
or a pro-inflammatory response by gut epithelial cells
[100]. Extrapolating these findings to critically ill and/or
extremely preterm neonates may not be appropriate, but
stopping the supplementation during an acute illness
(for example, proven or suspected sepsis, NEC, perinatal
asphyxia) may be in the best interest of the child, pend-
ing further evidence [101]. Studies are needed to identify
the optimal use of probiotics in such neonates.
Clinical monitoring during supplementation
Intolerance (higher osmotic load causing abdominal dis-
tension, diarrhea or vomiting), probiotic sepsis and AEs
(flatulence, loose stools) of additives such as prebiotic
oligosaccharides need to be monitored [102]. However,
the significant overlap of features of ileus of prematurity,
sepsis and NEC is expected to make this issue very diffi-
cult. Frequent clinical examinations and a cautious
approach are desirable until enough experience is
obtained with a probiotic product and protocol in this
high-risk cohort.
Ongoing laboratory surveillance for safety
On-site expert microbiological support is vital for inde-
pendent taxonomy confirmation, exclusion of contami-
nants and confirmation of colony counts in the
reconstituted product. Microbiology laboratories should
ensure that their culture media are capable of recovering
the constituent bacterial species, especially at low inocu-
lums from sterile sites. Additionally, they should be
familiar with the Gram stain and phenotypic appear-
ances of the probiotics in different media, and be aware
of the possible need for extended incubation times in
anaerobic conditions. In the few published reports of
bacteraemia with probiotics, there is scant detail about
the blood culture manufacturer or system or the media
used [103-106]. Clinical isolates should be compared
with probiotic strains using molecular methods such as
16S rRNA sequencing and pulsed-field gel electrophor-
esis [107]. The possibility of cross-contamination, result-
ing in nosocomial acquisition of probiotic strains by
other children in the neonatal unit, should not be for-
gotten. Kitajima et al. reported colonisation rates of 73%
and 91% in their probiotic group versus 12% and 44% in
the control group neonates at 2 and 6 weeks respec-
tively [52]. Costeloe et al. reported cross-contamination
rates of 35% in their pilot clinical trial. This possibility
needs to be discussed with the parents of the children
in neonatal units providing probiotic supplementation.
It is important for researchers to note that cross-con-
tamination in the control arm in an RCT is expected to
underestimate the true effects of probiotics [108]. Anti-
biotic susceptibility testing of probiotics by standardised
methods should be undertaken to provide local guidance
for empiric antibiotic prescribing [103-107,109,110]. The
frequency of in vivo transfer of antibiotic-resistance
mechanisms is currently unknown. The role of routine
fecal surveillance cultures to detect such transfer is also
unknown, and is likely to be beyond the scope of rou-
tine laboratories. Other important issues are the stability
of the probiotic on transport and shelf storage, ability of
the laboratory to rapidly detect probiotic sepsis, and sur-
veillance for the development of antibiotic resistance.
Regular random stool cultures are beneficial but need
extra resources. Compared with lactobacilli, culturing
bifidobacteria is difficult as it requires special media and
expertise [111]. The rarity of bifidobacterial sepsis in the
literature could relate to failure to isolate these strains
in blood culture by particular techniques. Newer non-
culture methods are a better option. Extensive ongoing
microbiological monitoring may not be necessary if the
safety and quality (from manufacturing, transport and
storage on-site to use in the neonatal unit) of the pro-
biotic product is ensured [82,112,113].
Practical issues
Variations in the manufacturing process can significantly
alter the properties of probiotic strains [51,112,114].
Variations between batches in the quality of dietary sup-
plements are also known to occur [115]. Assurance of
good manufacturing practices is thus important [116].
The choice of the packaging material plays an important
role in maintaining the viability of the probiotic strains
at sufficiently high levels to ensure their therapeutic
activity throughout shelf life. Probiotics, by current defi-
nition, are live microorganisms that survive in the anae-
robic environment of the gut, and are sensitive to
oxygen, moisture and heat. Their production and packa-
ging should therefore involve limiting their exposure to
oxygen by using barrier packages and eliminating oxy-
gen by flushing with nitrogen. The support compounds
should have minimal moisture. Refrigeration is impor-
tant to protect the product from significant temperature
fluctuations. The product format (dry powder, sachets,
ready-to-use liquid, capsules, tablets) is an important
issue, as we have recently reported poor viability of
strains in probiotic tablets [117].
Based on the current understanding that viability
(ability to survive, proliferate and benefit the host) is an
important property of probiotic strains, the proportion
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tial determinant of its clinical efficacy. This necessitates
a high degree of stringency in the manufacturing pro-
cess, as required by regulatory agencies. However, evi-
dence indicates that dead or inactivated probiotic
strains, or even their cellular components and culture
broths, can still have beneficial effects [118-120]. If
further clinical research provides evidence to this effect,
the proportion of viable strains in a probiotic product
may not be a crucial issue. However, it is important to
note that even if viability of the strains does not turn
out to be a crucial issue in the future, the level of strin-
gency required in the manufacturing process cannot be
compromised, because there are other important issues
involved, such as taxonomy confirmation and contami-
nation. Wastage after administration of a small dose,
and stability and contamination of the leftover dose are
also practical issues, and availability of a product in dif-
ferent strengths may solve this problem. Assurance of
r e g u l a rs u p p l ya n dr e a d ya v a i l a b i l i t yo fas t a n d b yp r o -
duct is important in view of the ongoing need for rou-
tine use and research, and prevention of inflation in
pricing due to the monopoly of one product.
Role of prebiotics in probiotic products
The coexistence of probiotics and prebiotics, as found in
human breast milk, is known to be synergistic [121,122].
Prebiotics have been shown to enhance the survival of
endogenous probiotic organisms [123,124]. Further
research, such as RCTs of probiotics versus synbiotics,
is necessary to evaluate whether addition of prebiotics
improves the survival and/or efficacy of probiotic strains
in preterm neonates [125].
Regulatory issues
There has been a poor track record of QC of some
commercially available products [126-128], thus impro-
visation and standardisation of the regulatory guidelines
is urgently needed. The first option involves the central
regulatory agencies (for example, in Australia, this is the
Therapeutic Goods Administration (TGA)) taking the
responsibility of approving the QC and quality assurance
(QA) practices in the manufacturing plant, and facilitat-
ing the development of a central QC laboratory for pro-
viding national backup services for independent ongoing
confirmation of quality. However, this option runs the
risks of administrative delays, overburdening of the cen-
tral laboratory, and complete dependency of all neonatal
units on its services. The second option involves devel-
opment of a central QC laboratory for each state to
supervise or assist the routine use of probiotics in the
state neonatal units. The third option is for each institu-
tion to develop its own on-site expertise within the fed-
eral regulatory guidelines. In countries such as the USA,
where probiotics (’intended to use to diagnose, cure,
mitigate, treat or prevent disease and affecting structure
or function of the body’) are registered as drugs rather
than food supplements, the regulatory restrictions on
the access to probiotics will be considerable [129,130].
Substantial delay in access to probiotics is inevitable in
such countries if phase I, II and III studies are to be
conducted before probiotics can be made easily available
[131,132]. Defining probiotics as ‘foods for specialised
health use’ as in Japan may overcome these difficulties
[133,134]. It is important to note that, although the reg-
ulatory restrictions will be more stringent if probiotics
are regulated as drugs, the regulations will then at least
be clear and consistently applied, and once licensed,
probiotics will potentially be more accessible to consu-
mers and physicians. Thus, in the longer term it may
actually be in the patients’ interest for probiotics to be
regulated as drugs under some circumstances.
We believe that with cooperation between govern-
ment, industry, scientists, and the International Probio-
tics Association, any one of these strategies could be
easily adopted to increase the availability of high-quality
probiotics if there is a political will to do so.
Other potentially useful strategies
Owing to the development of aberrant gut flora and
delayed colonisation by normal commensal strains in
preterm neonates, early preferential feeding with breast
milk and minimising exposure to antibiotics are crucial
to optimise the benefits of probiotic supplementation
[52]. Neonates given antibiotics at birth have been
reported to retain abnormal microbial flora 4 weeks
later, indicating the damaging effect of these agents
[135]. Strategies for preventing sepsis are also crucial in
optimising the benefits of probiotic supplementation, as
sepsis needs treatment with antibiotics (anti-probiotics)
[136]. The benefits of a standardised feeding protocol
must not be forgotten if prevention of NEC and facilita-
tion of enteral nutrition is the goal [137-142]. Such a
protocol will help in evaluation of the efficacy of probio-
tics in presence of different feeding policies. For neona-
tal units with donor milk banks, the effect of
pasteurisation on breast-milk probiotics needs to be stu-
died, given the thermal sensitivity of probiotic strains
[143]. Breast-milk oligosaccharides are not affected by
pasteurisation [144].
Data monitoring
Probiotic supplementation is a new development in neo-
natal intensive care. Hence, high-quality data monitoring
is essential to evaluate popu l a t i o no u t c o m e si nt h i s
high-risk cohort. Monitoring data during routine use is
similar to post-marketing surveillance, which has a
higher rate of detection of AEs (including rare ones)
[145], and is helpful in comparing the benefits and risks
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practices. Such data are essential to evaluate the effects
of the intervention at a local level, and for planning
future research. It is often a requirement of regulatory
agencies such as the TGA when an unlicensed drug is
used. The need for post-marketing surveillance has been
emphasised by expert committees [146]. Collaboration
between regional neonatal networks is crucial for link-
age of databases.
Information for parents
Based on the current evidence, parents are unlikely to
refuse probiotics, an intervention that substantially
reduces the incidence of death and life-threatening dis-
eases such as NEC [11,14]. Because of the lack of signifi-
cant experience with probiotics, especially in extremely
preterm neonates, and the currently unanswered ques-
tions surrounding this intervention, it is important to
ensure that parents are well informed about the benefits
and potential AEs, both short- and long-term. Honesty,
clarity and transparency in sharing information with the
parents, and respect for their autonomy are crucial.
Informed consent may be required until sufficient
experience has been obtained to provide probiotics as a
routine therapy without hesitation. Continued vigilance,
equivalent to post-marketing surveillance, and uniform
reporting are necessary to gain more data and confi-
dence with probiotic supplementation.
Role of placebo-controlled trials
The sum of the current evidence supports our view that
the role of placebo-controlled trials is necessary only for
the evaluation of new strains. From the purist’s point of
view, a large, definitive, placebo-controlled trial may be
justified for ELBW neonates in a setting of low baseline
risk, but given the current evidence and the difficulties
in obtaining fully informed consent from parents, suc-
cessful completion of such a trial in a realistic time
frame will be difficult. We have pointed out that the
issue of reproducibility in different settings has been
addressed adequately. Placebo-controlled trials are not
justified purely for evaluating the frequency and conse-
quences of cross-contamination. Allowing access to a
known, clinically effective, probiotic product also cannot
be the justification for such a trial, especially when spe-
cial regulatory schemes allow access to a life-saving
intervention. For addressing other important issues such
as defining the optimum intervention (which probiotic
(s), what dose and timing), and assessing microbial
adaptations and ecological consequences, interactions
with other preventive interventions and the effect of
probiotics on early development, other types of study
designs such as head to head trials (comparing different
products or protocols), cluster randomised and factorial
trials, cohort studies and long-term follow-up studies
are more suitable than placebo-controlled trials. The fre-
quency of cross-contamination in the placebo arm of a
RCT is important in this context. As for understanding
the mechanisms of the benefits of probiotics in the pre-
vention of NEC, it is important to note that the patho-
g e n e s i so fN E Cr e m a i n sp o o r l yu n d e r s t o o dd e s p i t e
extensive research for over three decades and that there
are multiple pathways by which probiotic(s) can provide
benefit [63]. There is a wide range of possible mechan-
isms that need further investigation, and several clinical
observations that cannot be satisfactorily explained at
the cellular level [75]. A large number of the mechan-
isms cannot be measured easily in humans for ethical or
feasibility reasons (for example, access to tissue
specimens).
Advancing knowledge by further research while not
denying probiotics to preterm neonates
High-quality definitive RCTs comparing issues such as
low versus high doses, single versus multiple strains, live
versus killed probiotic organisms [118,147], whole pro-
biotics versus probiotic components [148,149], probio-
tics versus prebiotics, probiotics versus synbiotics,
commencing supplementation ‘very early’ (starting on
day 1 of life if the severity of initial illness is not restric-
tive) versus starting ‘as early as possible’ (ready for ent-
eral feeds), and ‘enteral plus topical’ (oral spray) versus
‘only enteral’ supplementation, will advance the knowl-
edge in this area. A clear understanding of the benefits
and risks of probiotics will also be facilitated by the
advantages of prospective and robust data collection
during such research. Long-term issues such as NDI,
development of allergy, sensitisation and altered
immune responses also need to be monitored. The sig-
nificance of exposure of preterm neonates to lactose,
dextrin and cornstarch, which are used as carriers or
substrates in probiotic products, needs to be evaluated
[150].
Accessing probiotic products for research versus routine
use
Accessing a probiotic product (Table 2) may be rela-
tively easy in research rather than routine use, at least
until the regulatory issues are clarified. In Australia,
importing a probiotic is possible with clinical trial notifi-
cation approval from the TGA and a licence to import a
biological product from the Australian Quarantine and
Inspection Services. It is also possible in Australia, with
the local approval of the Drug and Therapeutics Com-
mittee and endorsement by the TGA of named clini-
cians as authorised prescribers, to obtain a probiotic
under a special access scheme. A similar scheme is pos-
sible in the UK. For a new product or strain, a very
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using it in this high-risk population. Small placebo-con-
trolled trials (rather than observational studies) will be
important to rigorously assess and confirm the ability of
the new strains to colonise the preterm gut if the pro-
duct is to be adopted for routine use. Even minor varia-
tions in the manufacturing process can compromise the
safety and efficacy of the product [51,67,112,151].
Conclusion
We have provided evidence-based guidelines (Table 3;
Table 4) for the use of probiotics in preterm neonates,
as we believe that the current evidence justifies routine
use of this intervention [18]. These guidelines will also
be helpful for optimal use of probiotics in research set-
tings. We believe that probiotics should be offered routi-
nely to all high-risk preterm neonates, taking into
account the unaddressed issues. The best way forward
could be to offer these products routinely but still
within a research framework to cover the current gaps
in knowledge [28]. It is important to note that most of
the unaddressed issues can be easily resolved by studies
not requiring a placebo.
The benefits of probiotics may not be dramatic in
neonatal units with a low incidence of all-cause mortal-
ity and definite NEC in preterm neonates for various
Table 3 Specific recommendations for major clinical decisions
Specific recommendations LOE
a[reference]
Selection of strains Combination containing Lactobacillus and at least one Bifidobacterium species is preferable.
Lactobacillus GG alone may not be effective
I [14]; II [55,56,60];
III-[3,15]
Dose 3 × 10
9 organisms per day, preferably in a single dose I [14]; II [55,56,60]
When to start? When the neonate is ready for enteral feeds, preferably within first 7 days of life I [14]; II [55,56,60];
III [3,15]
How long to continue? At least until 35 weeks corrected age, or discharge II [55,56,60]
Supplementation during
acute illness
Stopping the supplementation during an acute illness such as sepsis, NEC
bor perinatal asphyxia
may be safe
IV [94-98]
aLevel of evidence.
bNecrotising enterocolitis.
Table 4 Guidelines for other clinical and non-clinical issues
a
Guidelines References
1. Starting dose for ELBW
bneonates: 1.5 × 10
9 cfu/day
c until reaching 50-60 ml/kg/day feeds [84] and authors’ opinion
2. Osmotic load: solution should be diluted to keep the osmolality below 600 mOsm/L [86,87]
3. Diluent: sterile water or breast milk Authors’ opinion
4. Volume for administration: 1 to 1.5 ml per dose [86] and authors’ opinion
5. Clinical monitoring: patients should be monitored for intolerance (abdominal distension, diarrhea, vomiting),
probiotic sepsis, and adverse effects (flatulence, loose stools) of additives such as prebiotic oligosaccharides.
[95-101] and manufacturer
recommendation
6. Ongoing laboratory surveillance: Expertise in taxonomy confirmation (16S rRNA sequencing and PFGE
d), ruling
out contaminants, recovering probiotic strains at low inoculums from sterile sites, familiarity with the Gram stain
and phenotypic appearance of probiotics, and monitoring for antibiotic susceptibility/resistance and cross-
contamination are crucial.
[107]
7. Cold chain: maintenance of cold chain should be checked. Refrigerate at 4 to 10°C Manufacturer recommendation
8. Product stability: stability should be checked by regular microbiological tests [51,67,112,151]
9. Leftover solution should be discarded after giving small doses as it may get contaminated Manufacturer recommendation
10. Regulatory issues: importing may be easier for research than for clinical use. National regulations on drugs
and food supplements and customs quarantine guidelines should be checked
[131,132]
11. Data monitoring: high-quality data monitoring and collaboration between regional neonatal networks is
crucial for monitoring outcomes at a population level
[145,146]
12. Information for parents: parents should be kept well informed about benefits and adverse effects, including
the possibility of cross-contamination
[18,24]
13. Other potentially useful strategies: early preferential use of breast milk, strategies for prevention of sepsis,
standardised feeding protocols, avoidance of undue prolonged exposure to antibiotic
[137-142]
aLevel of evidence was applicable to specific recommendations for clinical issues (Table 3) and not to other guideline components discussed in Table 4 above.
bExtremely low birth weight.
cCFU: Colony forming units.
dPulsed-field gel electrophoresis.
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outcomes may be appropriate for probiotic research in
such neonatal units, because of the beneficial effects of
probiotics on the gastrointestinal tract [9,14,62,136-138].
Current evidence is inadequate in some areas of pro-
biotic supplementation. We have erred on the side of
safety in suggesting guidelines in these areas, taking into
consideration the basic principle: first, do no harm. We
wish to emphasise that ‘routine’ does not equate to
‘blind’ use of probiotics, a potentially powerful but dou-
ble-edged weapon in this high-risk population [19]. As
the debate around routine use of probiotics in preterm
neonates continues, countries such as Denmark have
already issued guidelines for use of probiotics in preterm
neonates [152]. If prevention of death and disease and
facilitation of nutrition is the goal, relying on a package
of potentially better practices rather than on probiotics
alone is essential [153,154].
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